SOURCE: Signal Watch

Signal Watch

August 02, 2011 08:53 ET

Analytical Reports on Valeant Pharmaceuticals International and Elan Corp. plc - High Volatility Seen in Many Drug Delivery Companies

NEW YORK, NY--(Marketwire - Aug 2, 2011) - www.SignalWatcher.com provides members with proprietary analysis of over 10,000 stocks which is updated every day. Today, members can receive their complimentary stock analysis on Valeant Pharmaceuticals International (NYSE: VRX) and Elan Corp. plc (NYSE: ELN). Sign up now on www.SignalWatcher.com to get your free reports on these stocks.

For many companies in the Healthcare Drug Delivery Sector, 2011 has been a year of tremendous growth. Companies in the sector such as Valeant Pharmaceuticals International and Elan Corp. plc have both substantially increased their stock prices over the last year. www.SignalWatcher.com gives traders a unique insight about Valeant Pharmaceuticals International and Elan Corp. plc by registering now at

http://signalwatcher.com/VRX/August022011.php or

http://signalwatcher.com/ELN/August022011.php.

The pharmaceuticals industry can be very volatile though, as issues with drug side effects can quickly take profitable drugs off the market. One such example is Elan's multiple sclerosis drug Tysabri which was temporarily taken off the market in 2005 after being tied to a possibly fatal brain disorder. Now that tests have been created to test patients' susceptibility to the disorder, sales of Tysabri have once again taken off and are driving profits for Elan.

www.SignalWatcher.com brings investors free classic analysis on Valeant Pharmaceuticals International, Elan Corp. plc and other companies within the Drug Delivery industry. This type of analysis is only a fragment of the information members have available to them. To learn more we encourage investors to sign up at http://signalwatcher.com/EmailSignup.php.

Another issue that many drug makers have to deal with is the expiration of their drug patents. Many high profile drugs could be going generic this year alone, and looking out for the companies that produce the name brand drugs as well as the generic versions of those drugs could be a key to success for investors.

About Signal Watch

Signal Watch's #1 goal is to help customers successfully engage the markets. For over 20 years, we have been developing the most powerful trading software available anywhere. But the software is only part of our mission. We also provide education and customer support designed to enable our customers to take control of their financial future.

Read our disclaimer by clicking on the following link http://www.signalwatch.com/disclaimers.aspx

Contact Information